Rapid genomic test cuts brain tumor diagnosis from 8 weeks to 2 hours
NHS pilots operating table diagnosis that could transform treatment timelines.
1Diagnostic breakthrough
A new genomic test developed by the University of Nottingham's Brain Tumour Research Centre reduces diagnosis time from 8 weeks to 2 hours. Performed during surgery, it analyzes tumor DNA through Oxford Nanopore's sequencing technology. The NHS is piloting this in five specialist centers, with plans for nationwide rollout. Primary brain tumors remain the leading cause of death for under-40s in the UK.
2Surgical decision advantage
The test provides neurosurgeons with detailed tumor genomic data while patients are still on the operating table. This real-time information allows immediate treatment planning, eliminating the traditional 4-8 week wait for pathology results. Consultant neurosurgeon Stuart Smith emphasizes this transforms surgical decision-making, particularly for aggressive tumors where time is critical.
3Technology mechanism
The shoebox-sized sequencer analyzes tumor tissue samples by passing DNA molecules through microscopic nanopores. This reveals the tumor's unique genetic signature within hours, compared to traditional histopathology methods requiring weeks. The Oxford Nanopore technology enables rapid genomic characterization without complex laboratory processing.
4Clinical trial acceleration
Early genomic diagnosis facilitates quicker enrollment in targeted clinical trials for eligible patients. The NHS highlights this could significantly improve outcomes for aggressive tumor types. Currently, many patients deteriorate during the diagnostic waiting period, becoming ineligible for experimental therapies that require early intervention.
5Initial rollout sites
Five NHS trusts are piloting the technology: Nottingham University Hospitals, University Hospitals Birmingham, Great Ormond Street, King's College Hospital, and Newcastle Hospitals. These centers were selected for their specialized neuro-oncology capabilities. Expansion to Bristol, Oxford, Leeds, and Manchester will follow evaluation of initial results.
6Patient impact
The test eliminates weeks of diagnostic uncertainty for patients and families. NHS Medical Director Prof Frankie Swords notes earlier treatment initiation could save lives, particularly for fast-growing tumors. For pediatric cases at Great Ormond Street, this represents a significant advancement in managing the UK's leading cause of childhood cancer death.
7Pathology workflow transformation
Traditional neuropathology methods involving microscopic analysis and immunohistochemistry are being augmented by genomic sequencing. The new approach maintains diagnostic accuracy while dramatically reducing turnaround time. This shift represents a broader trend toward molecular diagnostics in neuro-oncology.
8Future implications
Successful implementation could establish a new standard for brain tumor diagnosis globally. The NHS's adoption signals confidence in genomic medicine's potential to transform outcomes. As sequencing costs decrease, similar rapid diagnostics may emerge for other cancer types, potentially revolutionizing oncology care pathways.